Squamous Cell Carcinoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Squamous Cell Carcinoma

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Sub-indication: Head and Neck Cancer

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Kura Oncology, Inc.

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Squamous Cell Carcinoma Clinical Trial

Schedule an Appointment